Energy & Commerce Committee Closely Monitors First Post-McClellan ODAC Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Rep. Deutsch and Energy & Commerce Committee staffers get first row reserved seat at May 3 Genta’s Genasense and Allos’ Excelar meeting. Meeting serves as the litmus test for concerns that agency review process will “revert” to overregulation by FDA in post-Commissioner McClellan period.